CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy

ConclusionsThese results are consistent with the relatively few other large, population-based studies conducted to date that have not observed an increased risk of adverse BC outcomes associated with CYP2D6 inhibition.

http://link.springer.com/10.1007/s10552-018-1117-x

Source: Cancer Causes and Control - December 12, 2018 Category: Cancer & Oncology Source Type: research